



常在病情初發時，被誤診為其他疾病。過去幾年，醫學影像造影的技術已有長足進步，譬如：核磁共振(MRI)、正子掃描(PET scan)及核醫學的 Octer scan 等……，但 CgA 檢測在於神經內分泌系統診斷上仍獨具價值，以 CgA 為單一標記，即可精確診斷分佈於全身的神經內分泌細胞是否有不正常的分化，值得臨床上加以善用。在講求預防勝於治療的當今醫學價值觀點上，是不能再忽略 NETs 的診斷，進而對此非侵入性的檢測方法，並可提昇臨床上的方便性及重要診斷的價值。

誌謝

提供臨床醫師更有價值的非侵犯性診斷工具是各核醫實驗室之責任與使命感。感謝昶洋公司 Mr. Cliff 提供 CIS 原廠資料供本文使用，嘉惠同袍並促進醫學診斷品質之提昇，僅此致謝。

參考文獻

1. D'Herbomez M, Gouze V, Huglo D et al. Chromogranin-A assay and (123) I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma. *J Nucl Med* 2001;42:993-7.
2. Giovanella L, Ceriani L. Serum Chromogranin-A immunoradiometric assay in the diagnosis of pheochromocytoma. *Int J Biol Markers* 2002;17:130-4.
3. Luca Giovanella Nuclear imaging and serum chromogranin A in diagnosis of extra-adrenal Pheochromocytoma. 12th ICE INTERNATIONAL CONGRESS OF ENDOCRINOLOGY(September 4 th, 2004)
4. Pekic S, Damjanovic S, Djurovic M et al. Retroperitoneal malignant fibrous histiocytoma mimicking pheochromocytoma. *Endocrine*. 2004 Jun;24(1):99-103.
5. Wu JT, Astill ME, Liu GH, Stephenson RA. Serum chromogranin A : early detection of hormonal resistance in prostate cancer Patients. *Clin Lab Anal*. 1998;12(1):20-5.
6. Isshiki S et al. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for Pca. *J Urol* 2002;167(02):512-515.
7. Bonkhoff H, Fixemer T Neuroendocrine differentiation in prostate cancer : an unrecognized and therapy-resistant phenotype *Urologe* 2004;43(37):836-42.
8. Baudin E, Bidart JM, Bachelot A et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. *Ann Oncol* 2001;12(5S):S79-S83.
9. Bernini GP, Moretti A, Ferdeghnin M et al. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours. *British*